Researchers randomized 41 patients with bilateral severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy to a single posterior sub-Tenon capsule injection of Kenalog in one eye and no injection in the contralateral eye before panretinal photocoagulation. From baseline to six months, there was statistically significantly less change in logMAR BCVA and foveal thickness in the treatment group than in the control group. The authors conclude that the triamcinolone prevents PRP-induced macular thickening, and thereby results in less visual loss. British Journal of Ophthalmology, June 2009.